{"id":9458,"date":"2018-05-18T08:13:53","date_gmt":"2018-05-18T14:13:53","guid":{"rendered":"http:\/\/canadianglycomics.ca\/?p=9458"},"modified":"2019-08-01T11:16:24","modified_gmt":"2019-08-01T17:16:24","slug":"precision-therapeutics-subsidiary-tumorgenesis-announces-license-agreement-with-48hour-discovery","status":"publish","type":"post","link":"https:\/\/canadianglycomics.ca\/fr\/precision-therapeutics-subsidiary-tumorgenesis-announces-license-agreement-with-48hour-discovery\/","title":{"rendered":"Precision Therapeutics Subsidiary, TumorGenesis, Announces License Agreement with 48Hour Discovery"},"content":{"rendered":"
\"\"
The 48Hour Discovery team is based at the University of Alberta in Edmonton,.<\/figcaption><\/figure>\n

MINNEAPOLIS, March 15, 2018 (GLOBE NEWSWIRE) — Precision Therapeutics Inc.<\/a> (NASDAQ:AIPT<\/a>) (\u201cPrecision\u201d or \u201cthe Company\u201d), formerly Skyline Medical, announced today that its wholly owned subsidiary, TumorGenesis Inc., has secured a license agreement with 48Hour Discovery (\u201c48HD\u201d) which grants it access to 48HD\u2019s ligand discovery technology. This follows a license agreement with SyntArray, LLC, announced on March 13th<\/sup><\/a>, and is the latest milestone in the Company\u2019s strategy to bring together ground-breaking technologies to develop the next generation of patient derived (\u201cPDx\u201d) tumor models for precision cancer therapy and drug development.<\/p>\n

TumorGenesis is developing a new approach to growing tumor models in the laboratory that is faster, less costly and more closely mimics the characteristics of the patient\u2019s tumor, than the traditional PDx animal models that are currently on the market. TumorGenesis\u2019 innovative approach is comprised of three key steps: first, the tumor cells from the patient tumor biopsy are tagged using peptides targeted to the patient\u2019s specific cancer cells; second, the tags adhere the cells to a 3D biomimetic support in the well of a standard 96 well microplate; and third, the tumor cells are grown in the 3D culture system until ready for testing.<\/p>\n

The 48HD ligand discovery technology is vital to the first step in this process as it screens the patient\u2019s tumor cells against large peptide libraries to identify the specific peptide ligands that bind to those cells. Once identified by  48HD\u2019s technology, SyntArray\u2019s targeted peptide cell capture technology screens these peptides to determine the best combination that will capture the cancer cells and allow them to attach and grow on the 3D biomimetic support.<\/p>\n

Dr. Carl Schwartz, Chief Executive Officer of Precision Therapeutics, commented, \u201cTumorGenesis is developing a better way to grow tumors outside the human body so they mimic the environment inside the patients\u2019 body as closely as possible. This model is expected to create more accurate results when testing drugs for personalized therapy and when developing new drugs, compared to testing with traditional animal or cell culture models. The innovative 48HD technology allows us to capture all the heterogeneity of the tumor, including both the cancerous and non-cancerous cells. This is key to reassembling the tumor on an artificial \u2018scaffold\u2019, or 3D biomimetic support, so it grows in a way that closely mimics  the patient\u2019s body. This will allow us to offer a superior clinical testing environment which should drive lucrative partnerships with pharmaceutical companies as they develop new precision medicines and cancer therapies.\u201d<\/p>\n

Testing of patient tumors using the TumorGenesis approach is expected to:<\/p>\n

    \n
  1. Provide a personalized therapy protocol for a patient,<\/li>\n
  2. Provide high-quality data on cancer tumors for a platform based on the D-CHIP Artificial Intelligence (AI) platform of Helomics Corporation, pursuant to Precision Therapeutics\u2019 partnership with Helomics, and<\/li>\n
  3. Drive partnerships with Pharma companies for the development of new therapies, generating revenues for Precision Therapeutics.<\/li>\n<\/ol>\n

    The TumorGenesis PDx model will initially be developed for three orphan cancers, Multiple Myeloma, Triple-Negative Breast cancer (TNBC) and Ovarian cancers, all of which are areas that have a high unmet need for new and effective treatments that are tailored to patients\u2019 unique tumor profiles. Testing of the TumorGenesis PDx tumors will take place in collaboration with Helomics.<\/p>\n

    About Precision Therapeutics Inc.<\/strong><\/p>\n

    Precision Therapeutics (NASDAQ:AIPT<\/a>) operates in two business areas: first, applying artificial intelligence to personalized medicine and drug discovery to provide personalized medicine solutions for clients in the pharmaceutical, diagnostic, and biotech industries, and second, production of the FDA-approved STREAMWAY\u00ae System for automated, direct-to-drain medical fluid disposal.<\/p>\n

    Precision Therapeutics’ CRO services business is committed to improving the effectiveness of cancer therapy using the power of artificial intelligence (AI) applied to rich data diseases databases. This business has launched with Precision Therapeutics’ investment in Helomics Corporation, a precision diagnostic company and integrated clinical contract research organization whose mission is to improve patient care by partnering with pharmaceutical, diagnostic, and academic organizations to bring innovative clinical products and technologies to the marketplace.  In addition to its proprietary precision diagnostics for oncology, Helomics offers boutique CRO services that leverage our patient-derived tumor models, coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and a proprietary bioinformatics platform (D-CHIP) to provide a tailored solution to our client’s specific needs. Helomics is 25% owned by Precision Therapeutics.  Helomics\u00ae is headquartered in Pittsburgh, Pennsylvania where the company maintains state-of-the-art, CLIA-certified, clinical and research laboratories. For more information, please visit www.Helomics.com<\/a>. Precision Therapeutics has also announced the formation of a subsidiary, TumorGenesis to pursue a new rapid approach to growing tumors in the laboratory, which essentially \u201cfools\u201d the cancer cells into thinking they are still growing inside the patient. Precision Therapeutics and Helomics have also announced a proposed joint venture with GLG Pharma focused on using their combined technologies to bring personalized medicines and testing to ovarian and breast cancer patients, especially those who present with ascites fluid (over one-third of patients). The growth strategy in this business includes securing new partnerships and considering acquisitions in the precision medicine space.<\/p>\n

    Sold through the Skyline Medical business of Precision Therapeutics, The STREAMWAY System virtually eliminates staff exposure to blood, irrigation fluid and other potentially infectious fluids found in the healthcare environment. Antiquated manual fluid handling methods that require hand carrying and emptying filled fluid canisters present an exposure risk and potential liability. Skyline Medical’s STREAMWAY System fully automates the collection, measurement, and disposal of waste fluids and is designed to: 1) reduce overhead costs to hospitals and surgical centers; 2) improve compliance with OSHA and other regulatory agency safety guidelines; 3) improve efficiency in the operating room, and radiology and endoscopy departments, thereby leading to greater profitability; and 4) provide greater environmental stewardship by helping to eliminate the approximately 50 million potentially disease-infected canisters that go into landfills each year in the U.S.  For additional information, please visit www.skylinemedical.com<\/a>.<\/p>\n

    Forward-looking Statements<\/strong><\/p>\n

    Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the Company’s business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include risks related to the proposed joint ventures, including the need to negotiate the definitive agreements for the joint ventures; possible failure to realize anticipated benefits of the joint ventures; and costs of providing funding to the joint ventures. Other risks and uncertainties relating to the Company include, among other things, current negative operating cash flows and a need for additional funding to finance our operating plan; the terms of any further financing, which may be highly dilutive and may include onerous terms; unexpected costs and operating deficits, and lower than expected sales and revenues;  sales cycles that can be longer than expected, resulting in delays in projected sales or failure to make such sales; uncertain willingness and ability of customers to adopt new technologies and other factors that may affect further market acceptance, if our product is not accepted by our potential customers, it is unlikely that we will ever become profitable; adverse economic conditions; adverse results of any legal proceedings; the volatility of our operating results and financial condition; inability to attract or retain qualified senior management personnel, including sales and marketing personnel; our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the Company’s ability to implement its long range business plan for various applications of its technology; the Company’s ability to enter into agreements with any necessary marketing and\/or distribution partners and with any strategic or joint venture partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company’s technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission, which are available for review at www.sec.gov<\/a>.  This is not a solicitation to buy or sell securities and does not purport to be an analysis of the Company’s financial position. See the Company’s most recent Annual Report on Form 10-K, and subsequent reports and other filings at www.sec.gov<\/a>.<\/p>\n

    Contacts:<\/strong>
    \nInvestor Relations
    \nKCSA Strategic Communications
    \nElizabeth Barker
    \n(212) 896-1203
    \n    ebarker@kcsa.com<\/a><\/p>\n

    MONEYINFO, LLC
    \nCharles Moskowitz
    \n617-827-1296
    \n    info@moneyinfo-llc.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"

    MINNEAPOLIS, March 15, 2018 (GLOBE NEWSWIRE) — Precision Therapeutics Inc. (NASDAQ:AIPT) (\u201cPrecision\u201d or \u201cthe Company\u201d), formerly Skyline Medical, announced today that its wholly owned subsidiary, TumorGenesis Inc., has secured a license agreement with 48Hour Discovery (\u201c48HD\u201d) which grants it access to 48HD\u2019s ligand discovery technology. This follows a license agreement with SyntArray, LLC, announced on March 13th, and […]<\/p>\n","protected":false},"author":2,"featured_media":11445,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"footnotes":""},"categories":[200],"tags":[],"class_list":["post-9458","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-press-release","wpbf-post"],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t